Rinkeby School visits BioArctic

For the ninth consecutive year, BioArctic invited students and teachers from the Rinkeby School in Stockholm and hosted a visit at the company. The Rinkeby School ...

September – the World Alzheimer’s Month

Every fifth second someone in the world develops Alzheimer’s disease. There is a huge need for more research and effective treatments. September 2018 marks the seventh ...

September – the World Alzheimer’s Month

Every fifth second someone in the world develops Alzheimer’s disease. There is a huge need for more research and effective treatments. September 2017 marks the sixth ...

Jan Mattsson employed as CFO

Effective August 1, Jan Mattsson is employed by BioArctic as CFO. He has been working as CFO in the company as a consultant since February 2017.

US patent on Parkinson’s disease granted

BioArctic’s patent application encompassing treatment of Parkinson’s disease was granted in US 2016-04-19. The patent (US 9, 315, 569) covers treatment of Parkinson’s disease with an ...

BioArctic Receives Extended Funding from VINNOVA

In August 2015, VINNOVA announced that BioArctic Neuroscience AB together with the Ångström Laboratory, Department of Engineering Sciences, Uppsala University, and Psilox AB were granted extended ...

BioArctic Neuroscience receives major grant from EU

The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel treatment for complete spinal cord injury. This project has received funding (6.4 M€) from the ...

BioArctic Neuroscience receives grant from VINNOVA

In September 2014, VINNOVA announced that BioArctic Neuroscience AB together with the Ångström Laboratory, Department of Engineering Sciences, Uppsala University, and Psilox AB were granted up ...

BioArctic´s new facilities inaugurated

Last week, on April 28, BioArctic´s new offices and labs were inaugurated by Ewa Björling, Minister for Trade, Ministry for Foreign Affairs.

Alzheimer antibody enters into phase IIb

BioArctic’s monoclonal antibody for Alzheimer’s disease, BAN2401, has entered the next clinical study after successfully passed phase IIa. Safety and tolerability data indicate that BAN2401 is ...

BioArctic Receives Grant from VINNOVA

Today, VINNOVA announced that BioArctic Neuroscience AB was granted 3.5 million SEK for the clinical development of its proprietary product with the indication Treatment of Traumatic ...

Orphan Drug Designation in USA

Yesterday the FDA granted the request from BioArctic Neuroscience for orphan-drug designation of heparin activated recombinant human Fibroblast Growth Factor 1 (FGF1) in combination with a ...

BioArctic founds SpineMedical AB

SpineMedical AB is a 100 percent owned subsidiary to BioArctic Neuroscience AB. The company was founded to bring the new treatment and product for complete spinal ...

Huge interest for BioArctic / Eisai symposium

BioArctic presented a symposium together with its partner Eisai at the 10th International Conference on Alzheimer´s & Parkinson´s Diseases (AD/PD) in Barcelona March 9 - 13th. ...

FDA approves clinical study in Alzheimer patients

Today, FDA approved the first clinical study with BAN2401 in Alzheimer patients. BAN2401 is a humanized monoclonal antibody targeting the toxic protofibrils in Alzheimer´s disease. ...

BioArctic receives milestone

BioArctic receives 1st milestone payment from Eisai. In December 2007, BioArctic Neuroscience AB signed an exclusive license agreement with Eisai Co., Ltd, where first milestone payment ...

US vaccination patent approved

BioArctic s US patent on an Alzheimer vaccine was approved today. BioArctic Neuroscience AB has a proprietary technological platform for immunotherapy against misfolded proteins.

BioArctic rewarded

Today, VINNOVA announced that BioArctic Neuroscience AB was granted 1.9 million SEK for development of its proprietary product with the indication Treatment of Traumatic Spinal Cord ...

BioArctic initiates collaboration with GE

Stockholm, Sweden, June 3rd, 2009. BioArctic initiates collaboration with GE-Healthcare and Uppsala University on new diagnostics for Alzheimer´s disease. The intention is to create brain imaging ...

SME status to BioArctic

BioArctic Neuroscience AB has today been assigned SME status by EMEA. BioArctic is now eligible to benefit from the provisions for administrative and financial assistance laid ...

BioArctic moves to new facilities

BioArctic Neuroscience expands and increases office and lab space with 50%. On Dec 15th 2008 BioArctic moved to a brand new tailor-made site at Warfvinges väg ...

BioArctic expands. Recruits new scientists

BioArctic Neuroscience is a research company developing new drugs and diagnostics for neurodegenerative disorders. In 2007, a license agreement was signed with Eisai Co., Ltd., Japan, ...